{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 459985202
| image = Budesonide skeletal.svg
| width = 250
| alt = 
| image2 = Budesonide ball-and-stick.png
| width2 = 250
| alt2 = 
| caption = 

<!-- Clinical data -->
| pronounce = 
| tradename = Pulmicort, Rhinocort, Entocort 등
| Drugs.com = {{drugs.com|monograph|budesonide}}
| MedlinePlus = a608007
| DailyMedID = Budesonide
| pregnancy_AU = A
| pregnancy_AU_comment = /{{nbsp}}B3
| pregnancy_category = 
| routes_of_administration = [[경구 투여]], [[비강내 투여]], [[기관 삽관|기관내]], [[좌약|직장]], [[흡입제]]
| class = 
| ATC_prefix = A07
| ATC_suffix = EA06
| ATC_supplemental = {{ATC|D07|AC09}}, {{ATC|R01|AD05}}, {{ATC|R03|BA02}}

<!-- Legal status -->
| legal_AU = S2
| legal_AU_comment = /{{nbsp}}S4
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment = 
| legal_CA = Rx-only
| legal_CA_comment =<ref>{{웹 인용| title=Regulatory Decision Summary - Uceris | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00675 | access-date=4 June 2022 | archive-date=5 June 2022 | archive-url=https://web.archive.org/web/20220605060335/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00675 | url-status=live }}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM
| legal_UK_comment = 
| legal_US = OTC
| legal_US_comment = /&nbsp;Rx-only<ref name="Tarpeyo FDA label">{{웹 인용| title=Tarpeyo- budesonide capsule, delayed release | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938cada4-d6bf-4252-836f-dd40f9eadb4d | access-date=24 December 2021 | archive-date=25 December 2021 | archive-url=https://web.archive.org/web/20211225032829/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938cada4-d6bf-4252-836f-dd40f9eadb4d | url-status=live }}</ref><ref>{{웹 인용| title=Pulmicort Flexhaler- budesonide aerosol, powder | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54234b7d-3bcc-4809-1881-1d21484856a0 | access-date=24 December 2021 | archive-date=19 September 2021 | archive-url=https://web.archive.org/web/20210919024400/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54234b7d-3bcc-4809-1881-1d21484856a0 | url-status=live }}</ref><ref>{{웹 인용| title=Eohilia- budesonide suspension | website=DailyMed | date=9 February 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56f2023a-69b2-4470-b4ad-af7ec1be527a | access-date=26 February 2024 | archive-date=26 February 2024 | archive-url=https://web.archive.org/web/20240226052716/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56f2023a-69b2-4470-b4ad-af7ec1be527a | url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref name="Jorveza EPAR">{{웹 인용| title=Jorveza EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/jorveza | access-date=3 March 2023 | archive-date=4 March 2023 | archive-url=https://web.archive.org/web/20230304065613/https://www.ema.europa.eu/en/medicines/human/EPAR/jorveza | url-status=live }}</ref><ref name="Kinpeygo EPAR">{{웹 인용| title=Kinpeygo EPAR | website=[[European Medicines Agency]] (EMA) | date=17 May 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo | access-date=3 March 2023 | archive-date=4 March 2023 | archive-url=https://web.archive.org/web/20230304065605/https://www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo | url-status=live }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability = 10~20% ([[초회 통과 효과]])
| protein_bound = 85~90%
| metabolism = [[간]]의 [[CYP3A4]]
| metabolites = 
| onset = 
| elimination_half-life = 2.0~3.6시간
| duration_of_action = 
| excretion = [[소변]], [[대변]]

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51333-22-3
| CAS_supplemental = 
| PubChem = 40000
| IUPHAR_ligand = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01222
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4444479
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q3OKS62Q6X
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00246
| ChEBI = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1370
| NIAID_ChemDB = 
| PDB_ligand = 8W5
| synonyms = BUD

<!-- Chemical and physical data -->
| IUPAC_name = 11β,21-Dihydroxy-16α,17α-[butane-1,1-diylbis(oxy)]pregna-1,4-diene-3,20-dione
| C=25 | H=34 | O=6
| SMILES = CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
| StdInChI_comment = 
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VOVIALXJUBGFJZ-KWVAZRHASA
| density = 
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}

<!-- Definition and medical uses -->
'''부데소니드'''(budesonide)는 '''풀미코트'''(Pulmicort) 등 다양한 상품명으로 판매되는 [[당질 코르티코이드]] 약제이다.<ref name="AHFS20152">{{웹 인용|title=Budesonide |url=https://www.drugs.com/monograph/budesonide.html |url-status=live |archive-url=https://web.archive.org/web/20151128150235/http://www.drugs.com/monograph/budesonide.html |archive-date=28 November 2015 |access-date=2 December 2015 |publisher=The American Society of Health-System Pharmacists}}</ref> [[정량흡입기|흡입제]], [[분무제]], [[알약]], [[비강 스프레이]], [[좌약]] 등 다양한 제형이 존재한다.<ref name="AHFS20152" /><ref name="AHFS2015ENT2">{{웹 인용|title=Budesonide eent |url=https://www.drugs.com/monograph/budesonide-eent.html |url-status=live |archive-url=https://web.archive.org/web/20151208195318/http://www.drugs.com/monograph/budesonide-eent.html |archive-date=8 December 2015 |access-date=2 December 2015 |publisher=The American Society of Health-System Pharmacists}}</ref> 흡입제는 [[천식]]과 [[만성 폐쇄성 폐질환]](COPD)의 장기간 관리에 이용한다.<ref name="AHFS20152" /><ref>{{저널 인용|vauthors=De Coster DA, Jones M |date=2014 |title=Tailoring of corticosteroids in COPD management |journal=Current Respiratory Care Reports |volume=3 |issue=3 |pages=121–132 |doi=10.1007/s13665-014-0084-2 |pmc=4113685 |pmid=25089228}}</ref><ref>{{저널 인용|vauthors=Christophi GP, Rengarajan A, Ciorba MA |date=2016 |title=Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach |journal=Clinical and Experimental Gastroenterology |volume=9 |pages=125–30 |doi=10.2147/CEG.S80237 |pmc=4876845 |pmid=27274301 |doi-access=free}}</ref> 비강 스프레이 제제는 [[알레르기성 비염]]과 [[비용종]](코폴립) 치료에 쓰인다.<ref name="AHFS2015ENT2" /><ref>{{저널 인용|vauthors=Rudmik L, Schlosser RJ, Smith TL, Soler ZM |date=July 2012 |title=Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis |journal=The Laryngoscope |volume=122 |issue=7 |pages=1431–7 |doi=10.1002/lary.23259 |pmid=22410935 |s2cid=25637461}}</ref> [[변형방출제형|변형방출]] 알약이나 캡슐, 혹은 좌약 등은 [[크론병]], [[궤양성 대장염]], [[현미경적 대장염]] 같은 [[염증성 장 질환]]에 사용 가능하다.<ref name="Sil20112">{{저널 인용|vauthors=Silverman J, Otley A |date=July 2011 |title=Budesonide in the treatment of inflammatory bowel disease |journal=Expert Review of Clinical Immunology |volume=7 |issue=4 |pages=419–28 |doi=10.1586/eci.11.34 |pmid=21790284 |s2cid=32892611}}</ref><ref name="Pardi_20162">{{저널 인용|vauthors=Pardi DS, Tremaine WJ, Carrasco-Labra A |date=January 2016 |title=American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis |journal=Gastroenterology |volume=150 |issue=1 |pages=247–274.e11 |doi=10.1053/j.gastro.2015.11.006 |pmid=26584602}}</ref><ref name="BNF582">{{서적 인용|title=British national formulary: BNF 58 |date=2009 |publisher=British Medical Association |isbn=9780857111562 |edition=58 |pages=56–57}}</ref>

<!-- Side effects and mechanism -->
흡입제의 흔한 부작용에는 호흡기 감염, [[기침]], [[두통]]이 있다.<ref name="AHFS2015">{{웹 인용|title=Budesonide |url=https://www.drugs.com/monograph/budesonide.html |url-status=live |archive-url=https://web.archive.org/web/20151128150235/http://www.drugs.com/monograph/budesonide.html |archive-date=28 November 2015 |access-date=2 December 2015 |publisher=The American Society of Health-System Pharmacists}}</ref> 알약의 흔한 부작용은 [[피로감]], [[구토]], [[관절통]]이다.<ref name=AHFS2015/> 심각한 부작용은 감염 위험 증가, 골강도 감소, [[백내장]] 등이 있다.<ref name=AHFS2015/> 알약 제형을 장기간 사용할 시 [[부신기능부전]]에 빠질 수 있다.<ref name=AHFS2015/> 이 때문에 알약을 장기간 사용하다가 갑자기 사용 중단할 시 위험할 여지가 있다.<ref name=AHFS2015/> 흡입제는 [[임신]] 중 사용해도 안전하다고 여겨진다.<ref name=AHFS2015/> 부데소니드의 주된 약리학적 활성은 [[당질 코르티코이드]] 작용이다.<ref name=AHFS2015/>

<!-- Society and culture -->
부데소니드는 1973년 최초로 특허가 출원되었다.<ref>{{서적 인용| vauthors = Domeij B |title=Pharmaceutical patents in Europe|date=2000|publisher=Kluwer Law International|location=The Hague|isbn=9789041113481|page=278|url=https://books.google.com/books?id=KZfvZN2WfjcC&pg=PA278|url-status=live|archive-url=https://web.archive.org/web/20151208072850/https://books.google.ca/books?id=KZfvZN2WfjcC&pg=PA278|archive-date=8 December 2015}}</ref> 천식 치료약으로 상업적 사용이 시작된 것은 1981년이다.<ref>{{서적 인용| vauthors = Hamley P |title=Small Molecule Medicinal Chemistry: Strategies and Technologies|date=2015|publisher=John Wiley & Sons|isbn=9781118771693|page=390|url=https://books.google.com/books?id=LOudCgAAQBAJ&pg=PA390|url-status=live|archive-url=https://web.archive.org/web/20151208062120/https://books.google.ca/books?id=LOudCgAAQBAJ&pg=PA390|archive-date=8 December 2015}}</ref> [[WHO 필수 의약품 목록]]에 등재되어 있다.<ref name="WHO21st">{{서적 인용| vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free}}</ref> 일부 제형은 [[복제약]]으로도 이용 가능한 상태이다.<ref name=Ric2015>{{서적 인용| vauthors = Hamilton R |title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=451}}</ref><ref>{{웹 인용| title=First Generic Drug Approvals 2023 | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 May 2023 | url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals | archive-url=https://web.archive.org/web/20230630003621/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals | archive-date=30 June 2023 | url-status=live | access-date=30 June 2023}}</ref> 2021년 한 해 기준으로, 미국에서 200만 건 넘게 처방되면서 전체 약제 중 처방 횟수로 185등에 올랐다.<ref>{{웹 인용| title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{웹 인용| title = Budesonide - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Budesonide | access-date = 14 January 2024 | archive-date = 29 April 2017 | archive-url = https://web.archive.org/web/20170429130248/https://clincalc.com/DrugStats/Drugs/Budesonide | url-status = live }}</ref>

== 의학적 사용 ==
부데소니드는 [[천식]]의 유지 관리 및 예방적 치료를 위해 [[정량흡입기]]나 [[분무기]]로 투여한다. 특히 경구 [[코르티코스테로이드]] 치료가 필요하지만, 흡입제로 전신 투여 용량을 줄여 이득을 볼 수 있는 환자에게 유용하다.<ref>Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GiNA) 2011. Available at https://www.ginasthma.org {{webarchive|url=https://web.archive.org/web/20131014032230/http://www.ginasthma.org/ |date=14 October 2013}}</ref>

=== 염증성 장 질환 ===
지연방출 부데소니드 제형은 [[돌창자]] 또는 [[오름잘록창자]]를 침범한 경도에서 중등도의 활성 [[크론병]] 환자에게 유용하다.<ref>{{저널 인용| vauthors = Lichtenstein GR, Hanauer SB, Sandborn WJ | year = 2009 | title = Management of Crohn's Disease in Adults | journal = Am J Gastroenterol | volume = 104 | issue = 2| pages = 465–83 | pmid = 19174807 | doi=10.1038/ajg.2008.168| s2cid = 10176441| doi-access = free }}</ref> [[코크란 (단체)|코크란]] 리뷰에서는 최대 3개월간 유지 치료 시 크론병 관해에 유용하다는 근거를 발견했다.<ref name="pmid25141071">{{저널 인용| vauthors=Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, etal | title=Budesonide for maintenance of remission in Crohn's disease. | journal=Cochrane Database Syst Rev | year=2014 | volume=8 | issue= 8| pages=CD002913 | doi=10.1002/14651858.CD002913.pub3 | pmc=7133546 | pmid=25141071 }}</ref>

또한 활성 [[궤양성 대장염]] 환자의 관해 유도에 보조 약제로 사용 가능하다.<ref>{{저널 인용| vauthors = Habal FM, Huang VW | year = 2012 | title = Review Article: A Decision-Making Algorithm For the Management of Pregnancy in the Inflammatory Bowel Disease Patient | journal = Aliment Pharmacol Ther | volume = 35 | issue = 5| pages = 501–15 | pmid = 22221203 | doi=10.1111/j.1365-2036.2011.04967.x| s2cid = 34662981 | doi-access = free }}</ref>

[[현미경적 대장염]]에 대한 효과가 매우 뛰어나 관해 유도 및 유지 약제로 권고된다. 이는 [[림프구성 대장염]]과 [[교원성 대장염]] 두 형태 모두에 해당한다.<ref name="Pardi_2016">{{저널 인용|vauthors=Pardi DS, Tremaine WJ, Carrasco-Labra A |date=January 2016 |title=American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis |journal=Gastroenterology |volume=150 |issue=1 |pages=247–274.e11 |doi=10.1053/j.gastro.2015.11.006 |pmid=26584602}}</ref><ref>{{저널 인용| vauthors = Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, Bohr J, Bonderup O, Bouma G, D'Amato M, Heiberg Engel PJ, Fernandez-Banares F, Macaigne G, Hjortswang H, Hultgren-Hörnquist E, Koulaouzidis A, Kupcinskas J, Landolfi S, Latella G, Lucendo A, Lyutakov I, Madisch A, Magro F, Marlicz W, Mihaly E, Munck LK, Ostvik AE, Patai ÁV, Penchev P, Skonieczna-Żydecka K, Verhaegh B, Münch A | title = European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations | journal = United European Gastroenterology Journal | volume = 9 | issue = 1 | pages = 13–37 | date = February 2021 | pmid = 33619914 | pmc = 8259259 | doi = 10.1177/2050640620951905}}</ref>

=== 알레르기성 비염 ===
비강 스프레이 제형은 [[알레르기성 비염]] 치료제로 쓰인다.<ref>{{저널 인용| vauthors = Stanaland BE | title = Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review | journal = Clinical Therapeutics | volume = 26 | issue = 4 | pages = 473–92 | date = April 2004 | pmid = 15189745 | doi = 10.1016/s0149-2918(04)90050-1}}</ref>

=== 호산구성 식도염 ===
국소 부데노시드 투여는 [[호산구성 식도염]]에 상당한 치료 효과를 보인다.<ref>{{저널 인용| vauthors = Rawla P, Sunkara T, Thandra KC, Gaduputi V | title = Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies | journal = Drugs in R&D | volume = 18 | issue = 4 | pages = 259–269 | date = December 2018 | pmid = 30387081 | pmc = 6277325 | doi = 10.1007/s40268-018-0253-9}}</ref> 호산구성 식도염 치료용으로는 구강 내에서 분해 및 확산되는 알약 제형이 쓰이며, 상품명은 '''조베자'''(Jorveza)이다.<ref>{{drugs.com|uk|jorveza}}</ref>

=== IgA 신증 ===
부데소니드는 원발성 [[IgA 신증]](버거병)이 있고 질병의 빠른 진행 위험이 있는 성인 환자의 [[단백뇨]] 감소 목적으로 사용된다. 해당 목적의 제형은 미국에선 '''타르페요'''(Tarpeyo), 유럽에서는 '''킨페이고'''(Kinpeygo)라는 상품명으로 판매되고 있다.<ref name="Tarpeyo FDA label" /><ref>{{웹 인용| title=FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease | website=U.S. [[Food and Drug Administration]] (FDA) | date=17 December 2021 | url=https://www.fda.gov/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease | access-date=18 December 2021 | archive-date=19 December 2021 | archive-url=https://web.archive.org/web/20211219081148/https://www.fda.gov/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease | url-status=live }} {{PD-notice}}</ref><ref name="Kinpeygo EPAR" />

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{웹 인용| title=Budesonide Nasal Spray | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a601030.html }}
* {{웹 인용| title=Budesonide Oral Inhalation | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a699056.html }}

{{전거 통제}}
[[분류:알돌]]
[[분류:항천식제]]
[[분류:코르티코이드]]
[[분류:다이케톤]]
[[분류:다이올]]
[[분류:에논]]
[[분류:당질 코르티코이드]]
[[분류:희귀약]]
[[분류:프레그난]]
[[분류:아스트라제네카의 제품]]
[[분류:세계 보건 기구 필수 의약품]]